Press Release: Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, announced the expansion of its strategic partnership with Sim&Cure, a leading provider of advanced digital solutions for neurovascular therapy. The partnership between the two companies started 5 years ago and is now entering into a next phase with the aim to further enhance Philips’ position in the interventional neuro domain by integrating Sim&Size™ software into Philips’ next-generation Image-Guided Therapy platform – Azurion. The advanced connection offers care providers a more seamless, intuitive and efficient workflow for treating complex brain aneurysms. In addition, the two companies will be developing new synergies through common projects to drive innovation into the future of cathlabs.
Brain
aneurysms, which affect around 3-5% of the general population [1], pose
a significant challenge due to their complexity and the precision
required for device placement. Current planning and device selection
methods involve multiple manual steps, increasing both procedure time
and variability [2]. By integrating Sim&Size™ into Azurion,
physicians can now simulate device placement, optimize selection, and
guide deployment directly within the Azurion platform. This eliminates
the need for separate software and hardware setups, enabling greater
precision and efficiency in neurovascular procedures.
“The
strengthened collaboration with Sim&Cure allows us to bring the
power of simulation and image-guided therapy together in one platform,
enhancing physician confidence and improving patient outcomes,” said
Nicole Hermkens, VP Marketing IGT Systems at Philips. “By integrating
Sim&Size™ into our Azurion platform, we are reducing complexity and
variability in neurovascular procedures, ultimately helping to address
the growing burden of brain aneurysms.”
Philips is the global market leader in interventional suites.
Worldwide, Philips’ image-guided therapy solutions help treat one
patient every second, and for many of those, the Azurion platform is
being used. Since its launch in 2017, Azurion has been used to treat
more than five million patients in over 90 countries. Earlier this year,
Philips introduced
the latest version of Azurion, a biplane model designed specifically to
support neuro interventions. It features enhanced 2D and 3D imaging
capabilities, improved C-arm rotation flexibility, and optimized
workflow features to help clinicians perform complex neurovascular
procedures more effectively and efficiently.
With this
strengthened partnership, Philips continues to lead in stroke care and
interventional neuro therapies. This collaboration reflects Philips’
ongoing commitment to offering an integrated suite of solutions that support the entire stroke care pathway, from diagnosis and treatment to post-procedure monitoring.
More info here.